Abstract
Epigenetic alteration of tumor suppressor genes by promoter hypermethylation has played a key role in tumorigenesis, which is an important mechanism as indispensable as gene deletion and mutation. LRRC3B is a potential tumor suppressor gene newly discovered; however, the specific biologic function is still unknown. In the present study, we tested the expression levels of LRRC3B by methods associated with immunohistochemistry, Real-Time PCR, and methylation-specific polymerase chain reaction. Results showed that the expression levels were significantly low irrespective of methylation status, suggesting that there were other factors involved in this process. However, the expression profile of LRRC3B had a significant relationship with tissue grade, irrespective of the expressions of PR, CERB-2, VEGF, and Ki67 except in cases of p53 and ER, leading us to a conclusion that the abnormal expression of LRRC3B could serve as a useful marker for diagnosis and prognosis in breast carcinomas.
Similar content being viewed by others
References
Xu, Z. M., Yu, L., Lu, X. C., Han, W. D., Li, X. J., Jing, Y., et al. (2002). The application of Bioinformatics in studying the novel gene LRP15. Letters in Biotechnology, 13, 187–190.
Xu, Z. M., Yu, L., Lu, X. C., Han, W. D., Li, X. J., Jing, Y., et al. (2003). Cloning of the full length cDNA for a novel leukemia relapse-associated candidate gene LRP15. Zhongguo Shi Yan Xue Ye Xue Za Zhi, 11, 22–26.
Xu, Z. M., Yu, L., Lu, X. C., Dou, L. P., Li, M., Yang, L., et al. (2003). Analysis of LRP15 gene expression pattern and its expression in leukemia cells. Zhongguo Shi Yan Xue Ye Xue Za Zhi, 11, 583–586.
Kim, M., Kim, J. H., Jang, H. R., Kim, H. M., Lee, C. W., Noh, S. M., et al. (2008). LRRC3B, encoding a leucine-rich repeat-containing protein, is a putative tumor suppressor gene in gastric cancer. Cancer Research, 68, 7147–7155.
Tian, X. Q., Zhang, Y., Sun, D., Zhao, S., Xiong, H., & Fang, J. (2009). Epigenetic silencing of LRRC3B in colorectal cancer. Scandinavian Journal of Gastroenterology, 44, 79–84.
Ross, J. S., & Hortobagyi, G. N. (2005). Molecular oncology of breast cancer. Sudbury: Jones and Bartlett Publishers.
Jensen, E. V., & Jordan, V. C. (2003). The estrogen receptor: A model for molecular medicine. Clinical Cancer Research, 9, 1980.
Andersen, T. I., Holm, R., Nesland, J. M., Heimdal, K. R., Ottestad, L., & Børresen, A. L. (1993). Prognostic significance of TP53 alterations in breast carcinoma. British Journal of Cancer, 68, 540–548.
Overgaard, J., Yilmaz, M., Guldberg, P., Hansen, L. L., & Alsner, J. (2000). TP53 mutation is an independent prognostic marker for poor outcome in both node-negative and node-positive breast cancer. Acta Oncologica, 39, 327–333.
Wu, H., Cao, J., et al. (2002). The expression and significance of p53, CerbB-2, nm23 and ER in breast carcinomas. Journal of Guangdong Medical College, 8, 264–265.
Olivier, M., Langerød, A., Carrieri, P., Bergh, J., Klaar, S., Eyfjord, J., et al. (2006). The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clinical Cancer Research, 12, 1157–1167.
Acknowledgments
This study was supported by the National Key Basic Research Program of China (Grant 2010CB933902).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Wang, Y., Peng, Y., Zhou, Y. et al. The Clinical Value of LRRC3B Gene Expression and Promoter Hypermethylation in Breast Carcinomas. Cell Biochem Biophys 70, 1035–1041 (2014). https://doi.org/10.1007/s12013-014-0018-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12013-014-0018-1